Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments
-
Published:2024-04
Issue:4
Volume:484
Page:597-608
-
ISSN:0945-6317
-
Container-title:Virchows Archiv
-
language:en
-
Short-container-title:Virchows Arch
Author:
Rüschoff JosefORCID, Kumar George, Badve Sunil, Jasani Bharat, Krause Emma, Rioux-Leclercq Nathalie, Rojo Federico, Martini Maurizio, Cheng Liang, Tretiakova Maria, Mitchell Catherine, Anders Robert A., Robert Marie E., Fahy Darren, Pyle Mike, Le Quang, Yu Limin, Glass Benjamin, Baxi Vipul, Babadjanova Zulfia, Pratt James, Brutus Sergine, Karasarides Maria, Hartmann Arndt
Funder
Bristol-Myers Squibb
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Agilent Technologies (2021) PD-L1 IHC 22C3 pharmDx instructions for use. https://www.agilent.com/cs/library/packageinsert/public/P03951E_20.pdf . Accessed 27 Mar 2024 2. Agilent Technologies (2021) PD-L1 IHC 28–8 pharmDx instructions for use. https://www.agilent.com/cs/library/packageinsert/public/PD04163_rev_02_SK00521-5_IFU.pdf . Accessed 27 Mar 2024 3. Ahn S, Kim K-M (2021) PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28–8 pharmDx assays for responses to immunotherapy. Mod Pathol 34:1719–1727. https://doi.org/10.1038/s41379-021-00823-9 4. Bajorin DF, Witjes JA, Gschwend J, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat S, Park SH, Ye D, Agerbaek M, Collette S, Unsal-Kacmaz K, Zardavas D, Koon HB, Galsky MD (2021) First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol 39:Abstract 391. https://doi.org/10.1200/JCO.2021.39.6_suppl.391 5. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384:2102–2114. https://doi.org/10.1056/NEJMoa2034442
|
|